Paltimatrectinib

N/A

Report date: 2026/03/11 20:02:12
NME

Base Information

Drug NamePaltimatrectinib
Drug Alias NamePBI-200
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNerve growth factor receptor Trk-A inhibitorsNeurotrophic tyrosine kinase receptor type 2 inhibitorsNeurotrophic tyrosine kinase receptor type 3 inhibitors
TargetsNerve growth factor receptor Trk-ANeurotrophic tyrosine kinase receptor type 2Neurotrophic tyrosine kinase receptor type 3
Therapy Area/IndicationsSolid tumoursBrain NeoplasmsDesmoplastic Small Round Cell Tumor
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSingaporeItaly +[11] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesPyramid Biosciences
China Registration ClassN/A

Develop Information

Active CompaniesPyramid Biosciences
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsBrain NeoplasmsDesmoplastic Small Round Cell Tumor

Other Information

ATC CodeN/A
Related LinksN/A